<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        25-355-01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2001
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ETOPOSID "EBEWE" 20MG-ML VIAL
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ETOPOSIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        42.6
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value=" Fareva Unterach GmbH " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                             Fareva Unterach GmbH 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            EBEWE PHARMA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01CB01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The name of this medicine is Etoposid &ldquo;Ebewe&rdquo;. Each vial contains Etoposide.</p><p>&nbsp;</p><p>Etoposide belongs to the group of medicines called cytostatics which are used in the treatment of cancer.</p><p>&nbsp;</p><p>Etoposid &ldquo;Ebewe&rdquo; is used in the treatment of certain types of cancers in adults:</p><p>&nbsp;</p><p>- testicular cancer</p><p>- small cell lung cancer</p><p>- cancer of the blood (acute myeloid leukaemia)</p><p>- tumour in the lymphatic system (Hodgkin&rsquo;s lymphoma, non-Hodgkin&rsquo;s lymphoma)</p><p>- reproductive system cancers (gestational trophoblastic neoplasia and ovarian cancer)</p><p>&nbsp;</p><p>Etoposid &ldquo;Ebewe&rdquo; is used in the treatment of certain types of cancers in children:</p><p>&nbsp;</p><p>- cancer of the blood (acute myeloid leukaemia)</p><p>- tumour in the lymphatic system (Hodgkin&rsquo;s lymphoma, non-Hodgkin&rsquo;s lymphoma)</p><p>&nbsp;</p><p>The exact reason why you have been prescribed Etoposid &ldquo;Ebewe&rdquo; is best discussed with your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Etoposid &ldquo;Ebewe&rdquo;:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic to etoposide or any of the other ingredients of this medicine (listed in section 6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have recently been given a live vaccine, including Yellow fever vaccine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are breast-feeding or planning to breast-feed.</p><p>&nbsp;</p><p>If any of the above affects you, or if you are unsure if they do, tell your doctor who will be able to advise you.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor, pharmacist or nurse before receiving Etoposid &ldquo;Ebewe&rdquo;:</p><p>&nbsp;</p><p>- if you have any <strong>infections</strong>.</p><p>- if you have had <strong>radiotherapy or chemotherapy </strong>recently.</p><p>- if you have low levels of a protein called <strong>albumin </strong>in your blood.</p><p>- if you have liver or kidney problems.</p><p>&nbsp;</p><p>Effective anti-cancer treatment can destroy cancer cells rapidly in large numbers. On very rare occasions this may cause harmful amounts of substances from these cancer cells to be released into the blood. If this happens it can cause problems with the liver, kidney, heart or blood, which may result in death if not treated.</p><p>&nbsp;</p><p>In order to prevent this, your doctor will need to do regular blood tests to monitor the level of these substances during treatment with this medicine.</p><p>&nbsp;</p><p>This medicine can cause a reduction in the level of some blood cells, which could cause you to suffer from infections, or may mean that your blood doesn&rsquo;t clot as well as it should if you cut yourself. Blood tests will be taken at the start of your treatment, and before each dose you take, to make sure that this isn&rsquo;t happening.</p><p>&nbsp;</p><p>If you have reduced liver or kidney function, your doctor may also want you to take regular blood tests to monitor these levels.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and Etoposid &ldquo;Ebewe&rdquo;</strong></p><p>Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>This is especially important</p><p>&nbsp;</p><p>- if you are taking a medicine called ciclosporin (a drug used to reduce the activity of the</p><p>&nbsp;&nbsp; immune system).</p><p>- if you are being treated with cisplatin (a medicine used to treat cancer).</p><p>- if you are taking phenytoin or any other medicines used to treat epilepsy.</p><p>- if you are taking warfarin (a medicine used to prevent blood clots from forming).</p><p>- if you have recently been given any live vaccines.</p><p>- if you are taking phenylbutazone, sodium salicylate, or aspirin.</p><p>- if you are taking any anthracyclines (a group of medicines used to treat cancer).</p><p>- if you are taking any drugs with a similar mechanism of action as ETOPOPHOS and</p><p>&nbsp;&nbsp; associated names.</p><p>&nbsp;</p><p><strong>Pregnancy, breast-feeding and fertility </strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p>Etoposid &ldquo;Ebewe&rdquo; must not be used during pregnancy unless clearly indicated by your doctor.</p><p>&nbsp;</p><p>You must not breastfeed while you are receiving Etoposid &ldquo;Ebewe&rdquo;.</p><p>&nbsp;</p><p>Both male patients and female patients of child-bearing age should use an effective contraceptive method (<em>e.g</em>., the barrier method or condoms) during treatment and for at least 6 months after the end of treatment with Etoposid &ldquo;Ebewe&rdquo;.</p><p>&nbsp;</p><p>Male patients treated with Etoposid &ldquo;Ebewe&rdquo; are advised not to father a child during treatment and for up to 6 months after treatment. In addition, men are advised to seek counselling on sperm preservation before starting treatment.</p><p>&nbsp;</p><p>Both male and female patients who are considering having a child after having treatment with Etoposid &ldquo;Ebewe&rdquo; should discuss this with their doctor or nurse.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>No studies on the effects on the ability to drive and use machines have been performed. However, if you feel tired, sick to your stomach, dizzy or light-headed you should not do so until you have discussed it with your doctor.</p><p>&nbsp;</p><p>&nbsp;This medicinal product contains 33 vol % ethanol (alcohol), i.e. up to 2345 mg per 180mg (average dose), equivalent to 37ml of beer, 15ml of wine per average dose.</p><p>&nbsp;</p><p>Harmful for those suffering from alcoholism.</p><p>&nbsp;</p><p>To be taken into account in pregnant or breastfeeding women, children and high risk groups such as patients with liver disease or epilepsy.</p><p>&nbsp;</p><p>The amount of alcohol in this medicinal product may alter the effects of other medicines.</p><p>&nbsp;</p><p>The amount of alcohol in this medicinal product may impair your ability to drive or use machines.</p><p>&nbsp;</p><p>This medicinal product contains 20mg benzyl alcohol in each ml which is equivalent to 180mg per 9ml (average dose).&nbsp;</p><p>&nbsp;</p><p>Benzyl alcohol may cause allergic reactions.</p><p>&nbsp;</p><p>Benzyl alcohol has been linked with the risk of severe side effects including breathing problems (called &ldquo;gasping syndrome&rdquo;) in young children.</p><p>&nbsp;</p><p>It should not be given to your newborn baby (up to 4 weeks old), unless recommended by your doctor.</p><p>&nbsp;</p><p>Should not be used for more than a week in young children (less than 3 years old), unless advised by your doctor or pharmacist.</p><p>&nbsp;</p><p>Ask your doctor or pharmacist for advice if you are pregnant or breast-feeding. This is because large amounts of benzyl alcohol can build up in your body and may cause side effects (called &ldquo;metabolic acidosis&rdquo;).</p><p>&nbsp;</p><p>Ask your doctor or pharmacist for advice if you have a liver or kidney disease. This is because large amounts of benzyl alcohol can build up in your body and may cause side effects (called &ldquo;metabolic acidosis&rdquo;).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Etoposid &ldquo;Ebewe&rdquo; will be given to you by a doctor or nurse. It will be given as a slow infusion into a vein. This may take between 30 to 60 minutes.</p><p>&nbsp;</p><p>The dose you receive will be specific to you, which the doctor will calculate. The usual dose, based on etoposide, is 50 to100mg/m<sup>2 </sup>body surface area, daily for 5 days in a row or 100 to 120 mg/ m<sup>2</sup> body surface area on days 1, 3 and 5. This course of treatment may then be repeated, depending on the results of blood tests, but this will not be for at least 21 days after the first course of treatment.</p><p>&nbsp;</p><p>For children being treated for cancer of the blood or lymphatic system the dose used is 75 to 150 mg/m<sup>2</sup> body surface area daily for 2 to 5 days.</p><p>&nbsp;</p><p>The doctor may sometimes prescribe a different dose particularly if you are receiving, or have received, other treatments for your cancer or if you have kidney problems.</p><p>&nbsp;</p><p><strong>If you are given more </strong><strong>Etoposid &ldquo;Ebewe&rdquo;</strong><strong> than you should </strong></p><p>&nbsp;</p><p>As Etoposid &ldquo;Ebewe&rdquo; is given to you by a doctor or nurse, overdose is unlikely. However, if this does occur your doctor will treat any symptoms that follow.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Tell your doctor or nurse immediately if you get any of the following symptoms: swelling of your tongue or throat, breathing difficulties, fast heartbeat, flushing of the skin or a rash. These may be signs of a severe allergic reaction. </strong></p><p>Severe <strong>liver, kidney or heart damage </strong>from a condition called tumour lysis syndrome, caused by harmful amounts of substances from the cancer cells getting into the blood stream, has been seen sometimes when Etoposid &ldquo;Ebewe&rdquo; is taken along with other drugs used to treat cancer.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Possible side effects </strong>experienced with Etoposid &ldquo;Ebewe&rdquo; that are;</p><p>&nbsp;</p><p><strong>Very common side effects </strong>(may affect more than 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood disorders (this is why you will be having blood tests between courses of treatment)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea and vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; temporary hair loss</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; damage to the liver</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased liver enzymes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Jaundice (increased bilirubin)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in skin colour (pigmentation)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling weak (asthenia),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Generally feeling unwell (malaise)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal pain</p><p>&nbsp;</p><p><strong>Common side effects </strong>(may affect up to 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute leukaemia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reactions at the site of infusion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Irregular heart beat (arrhythmia), or a heart attack (myocardial infarction)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe allergic reactions</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sore lips, mouth or throat ulcers</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin problems such as itching or rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of a vein</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infection</p><p>&nbsp;</p><p><strong>Uncommon side effects </strong>(may affect up to 1 in 100 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tingling or numbness in hands and feet</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bleeding</p><p>&nbsp;</p><p><strong>Rare side effects </strong>(may affect up to 1 in 1,000 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acid reflux</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flushing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe allergic reactions</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Convulsions (seizure)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sleepiness or tiredness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Temporary blindness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serious reactions of the skin and/or mucous membranes which may include painful blisters and fever, including extensive detachment of the skin (Stevens-Johnson syndrome and toxic epidermal necrolysis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a sunburn-like rash that may occur on skin that has previously been exposed to radiotherapy and can be severe (radiation recall dermatitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Difficulty swallowing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A change in the way things taste</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breathing problems</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Not known</strong> (frequency cannot be estimated from the available data)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tumour lysis syndrome (complications of substances released from treated cancer cells entering the blood)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; face and tongue swelling</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infertility</p><p>-&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;difficulty breathing</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and vial after EXP. The expiry date refers to the last day of that month.</p><p><strong>&nbsp;</strong></p><p>Etoposid &ldquo;Ebewe&rdquo; will be stored in the pharmacy and made up in a special area before the doctor or nurse gives it to you.</p><p>&nbsp;</p><p>Store below 25&deg;C. Store in the original package.</p><p><strong><em>Shelf life for diluted solutions: 24 hours at 2 to 8&deg;C</em></strong></p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is etoposide.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are benzyl alcohol, ethanol 96%, anhydrous citric acid, macrogol 300, polysorbate 80.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Etoposid “Ebewe” is a clear, light yellow solution.

Pack sizes: 
Individual pack containing 1 vial with 50 mg/2.5 ml, 100 mg/5ml, 200 mg/10 ml.

Multi packs containing 5 or 10 vials with 50 mg/2.5 ml, 100 mg/5ml, 200 mg/10 ml.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong><br />EBEWE Pharma Ges.m.b.H. Nfg.KG<br />A-4866 Unterach, AUSTRIA</p><p><strong>Manufacturer</strong><br />Fareva Unterach GmbH<br />4866 Unterach, AUSTRIA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                July 2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">اسم هذا الدَّواء هو إيتوبوسايد &quot;إيبيفيه&quot;. تحتوي كل زجاجة على عقار إيتوبوسايد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينتمي عقار إيتوبوسايد إلى مجموعة من الأدوية تُدعى مثبطات نمو الخلايا التي يتم استخدامها في علاج السرطان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستخدم عقار إيتوبوسايد &quot;إيبيفيه&quot; في علاج أنواع مُعَيّنة من السرطانات في البالغين:</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الخصية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الرئة ذو الخلايا الصغيرة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الدَّم (سرطان الدَّم النخاعي الحاد).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ورم بالجهاز الليمفاوي (سرطان الغدد الليمفاوية الهودجكين، سرطان الغدد الليمفاوية غير الهودجكين).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطانات الجهاز التَّناسلي (ورم الأرومة الغاذية الحملي وسرطان المبيض).</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستخدم عقار إيتوبوسايد &quot;إيبيفيه&quot; في علاج أنواع مُعَيّنة من السرطانات في الأطفال:</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الدَّم (سرطان الدَّم النخاعي الحاد).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ورم بالجهاز الليمفاوي (سرطان الغدد الليمفاوية الهودجكين، سرطان الغدد الليمفاوية غير الهودجكين).</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُفضل مناقشة السبب المُحدد وراء وصف عقار إيتوبوسايد &quot;إيبيفيه&quot; لك مع الطبيب الخاص بك.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا تتلقى عقار إيتوبوسايد &quot;إيبيفيه&quot; في الحالات الآتية:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه إيتوبوسايد أو تجاه أي مكون من المكونات الأخرى الموجودة بهذا الدَّواء (المدرجة في قسم: 6).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تم إعطاؤك مؤخرًا أحد اللقاحات الحيّة، بما في ذلك لقاح الحُمّى الصفراء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ مرضعًا أو<strong> </strong>تخططين للإرضاع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا تعرضت لأي مما سبق أو إذا لم تكن متأكدًا من ذلك، فأخبر طبيبك الذي بدوره سيكون قادرًا على تقديم المشورة لك.</p><p dir="RTL">&nbsp;</p><p><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">تحدَّث إلى طبيبك أو الصيدلي أو الممرض(ة) الخاص(ة) بك قبل تلقي عقار إيتوبوسايد &quot;إيبيفيه&quot;:</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أي <strong>عدوى</strong>.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد تلقيت مؤخرًا <strong>علاجًا إشعاعيًّا أو علاجًا كيميائيًّا</strong>.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من انخفاض مستويات بروتين يُدعى <strong>الألبومين</strong> لديك بالدَّم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك مشاكل بالكبد أو الكُلى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن للعلاج الفعّال المُضاد للسرطان تدمير الخلايا السرطانية بسرعة وبأعداد كبيرة. في حالات نادرة جدًّا، قد يتسبب ذلك في إفراز الخلايا السرطانية هذه لكميات ضارة من المواد في الدَّم. قد يسبب ذلك في حال حدوثه مشاكل بالكبد، الكُلى، القلب أو الدَّم مما قد يُؤدي إلى حدوث الوفاة إذا لم يتم علاجه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">للوقاية من ذلك، سيتعين على طبيبك إجراء اختبارات دم بصفة منتظمة؛ لمراقبة مستوى هذه المواد أثناء الخضوع للعلاج بهذا الدَّواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يسبب هذا الدَّواء انخفاضًا في مستوى بعض خلايا الدَّم، مما قد يتسبب في إصابتك بعدوى أو مما قد يعني أن الدم لديك لن يتجلط كما ينبغي إذا جرحت نفسك. سيتم إجراء اختبارات بالدم عند بدء علاجك وقبل تلقيك لكل جرعة؛ للحرص على عدم حدوث ذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تعاني من قصور في وظائف الكبد أو الكُلى، فقد يرغب طبيبك أيضًا في أن تخضع لاختبارات دم بصفة منتظمة لمراقبة هذه المستويات.</p><p dir="RTL">&nbsp;</p><p><strong>استخدام أدوية أخرى مع عقار إيتوبوسايد &quot;إيبيفيه&quot;</strong></p><p dir="RTL">يُرجى إخبار طبيبك أو الصيدلي أو الممرض(ة) الخاص(ة) بك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أيَّة أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُعد ذلك مهمًّا بشكل خاص.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول دواءً يُدعى سيكلوسبورين (عقار يُستخدَم للحد من نشاط الجهاز المناعي).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تخضع للعلاج بسِيسْبلاتين (دواء يُستخدَم لعلاج السرطان).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول فينيتوين أو أية أدوية أخرى تُستخدَم لعلاج الصرع.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول وارفارين (دواء يُستخدَم لمنع تكون الجلطات الدَّموية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تم إعطاؤك مؤخرًا أية لقاحات حيّة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول فينيل بوتازون، ساليسيلات الصوديوم أو الأسبرين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أيًّا من الأنثراسيكلينات (مجموعة من الأدوية تُستَخدَم لعلاج السرطان).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أية عقاقير ذات آلية عمل مماثلة لتلك الخاصة بإيتوبوفوس والأسماء ذات الصلة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرَّضاعة الطبيعية والخصوبة </strong></p><p dir="RTL">إذا كنتِ حاملًا أو مرضعًا، أو تعتقدين أنكِ قد تكونين حاملًا أو تخططين لذلك، فاستشيري طبيبك أو الصيدلي الخاص بك قبل تلقي هذا الدَّواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عدم استخدام عقار إيتوبوسايد &quot;إيبيفيه&quot; أثناء فترة الحمل ما لم يُشِر طبيبكِ إلى ذلك بوضوح.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عليكِ تجنُّب ممارسة الرضاعة الطبيعية أثناء تلقيكِ العلاج بعقار إيتوبوسايد &quot;إيبيفيه&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي على كل من المرضى الذكور والإناث بعُمْر الإنجاب استخدام وسيلة فعالة لمنع الحمل (<em>على سبيل المثال</em><em>:</em> وسيلة عازلة أو الواقي) أثناء الخضوع للعلاج ولمدة 6 أشهر على الأقل بعد انتهاء العلاج بعقار إيتوبوسايد &quot;إيبيفيه&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُنصَح المرضى من الذكور الخاضعين للعلاج بعقار إيتوبوسايد &quot;إيبيفيه&quot; بعدم الإنجاب أثناء العلاج ولمدة 6 أشهر بعد التَّوقف عن العلاج. بالإضافة إلى ذلك، يُنصح الرجال بطلب المشورة حول حفظ الحيوانات المنوية قبل بدء العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي على كل من المرضى الذكور والإناث الذين يخططون للإنجاب بعد الخضوع للعلاج بعقار إيتوبوسايد &quot;إيبيفيه&quot; مناقشة ذلك مع الطبيب أو الممرض(ة) الخاص(ة) بهم.</p><p dir="RTL">&nbsp;</p><p><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">لم يتم إجراء أيَّة دراسات بشأن التَّأثيرات في القدرة على القيادة واستخدام الآلات. مع ذلك، إذا شعرت بالتَّعب، الإعياء بمعدتك، الدوخة أو خفة الرَّأس، ينبغي عليك ألا تمارس القيادة أو تستخدم الآلات حتى تتناقش مع طبيبك.</p><p dir="RTL">&nbsp;</p><p>&nbsp;يحتوي هذا المنتج الدَّوائي على 33٪ من حجمه إيثانول (كحول) أي، ما يصل إلى 2345 مجم لكل 180 مجم (متوسط الجرعة)، بما يُعادِل 37 مللي لتر من الجعة أو 15 مللي لتر من النبيذ لمتوسط الجرعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يكون هذا ضارًّا بالنسبة لأولئك الذين يعانون من إدمان الكحوليات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب مراعاة ذلك بالنسبة للسيدات من الحوامل أو المرضعات والأطفال والمجموعات المعرضين لخطورة مرتفعة مثل المرضى الذين يعانون من أحد أمراض الكبد أو الصَّرع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن لكمية الكحول الموجودة في هذا المنتج الدَّوائي أن تغير من تأثيرات الأدوية الأخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تُؤدي كمية الكحول الموجودة في هذا المُنتَج الدَّوائي إلى إضعاف قدرتك على ممارسة القيادة أو استخدام الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي هذا المنتج الدَّوائي على 20 مجم من الكحول البنزيلي بكل مللي لتر أي ما يعادل 180 مجم لكل 9 مللي لتر (متوسط الجرعة).&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يسبب الكحول البنزيلي تفاعلات حساسية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">اقترن استخدام الكحول البنزيلي بخطر التَّعرض لآثار جانبية شديدة بما في ذلك مشاكل التنفس (تُدعى &quot;متلازمة اللهاث&quot;) في الأطفال صغار السن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي عدم إعطائه لحديثي الولادة (ممن تصل أعمارهم إلى 4 أسابيع)، ما لم يوص طبيبك بذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">كما ينبغي عدم استخدامه لأكثر من أسبوع واحد في الأطفال صغار السن (أقل من 3 أعوام)، ما لم ينصح طبيبك أو الصيدلي الخاص بك بذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">اطلبي المشورة من طبيبكِ أو الصيدلي الخاص بكِ إذا كنتِ حاملًا أو مرضعًا. يرجع ذلك إلى أن الكميات الكبيرة من الكحول البنزيلي يمكن أن تتراكم في جسمك وقد تسبب آثارًا جانبية (تسمى: &quot;الحُماض الاستقلابي&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL">استشر طبيبك أو الصيدلي الخاص بك إذا كان لديك مرض بالكبد أو الكُلى. يرجع ذلك إلى أن الكميات الكبيرة من الكحول البنزيلي يمكن أن تتراكم في جسمك وقد تسبب آثارًا جانبية (تسمى &quot;الحُماض الاستقلابي&quot;).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيتم إعطاؤك عقار إيتوبوسايد &quot;إيبيفيه&quot; من قِبَل الطبيب أو الممرض(ة). سيتم إعطاؤه على هيئة تسريب بطيء في الوريد. قد يستغرق ذلك ما يتراوح بين 30 و60 دقيقة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة التي ستتلقاها ستكون مُحددة لك وسيحسبها الطبيب. تبلغ الجرعة المعتادة، استنادًا إلى عقار إيتوبوسايد، ما يتراوح بين 50 و100 مجم/ متر<sup>2</sup> من مساحة سطح الجسم، يوميًّا لمدة 5 أيام على التوالي أو ما يتراوح بين 100 و120 مجم/ متر<sup>2</sup> من مساحة سطح الجسم في اليوم 1، 3 و5. يمكن بعد ذلك إعادة هذه الدورة العلاجية، اعتمادًا على نتائج اختبارات الدَّم، إلا أنه لن تتم إعادتها إلا بعد انقضاء 21 يومًا على الأقل من الدورة العلاجية الأولى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بالنسبة للأطفال الذين يتم علاجهم من سرطان الدم أو الجهاز الليمفاوي، تبلغ الجرعة المُستخدمة ما يتراوح بين 75 و150 مجم/ متر<sup>2</sup> من مساحة سطح الجسم يوميًّا لمدة تتراوح بين يومين و5 أيام.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يصف الطبيب أحيانًا جرعة مختلفة خاصةً إذا كنت تتلقى أو كنت قد تلقيت علاجات أخرى للسرطان الذي تعاني منه أو إذا كنت تعاني من مشاكل بالكُلى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تم إعطاؤك كمية أكبر مما ينبغي من عقار إيتوبوسايد </strong><strong>&quot;</strong><strong>إيبيفيه</strong><strong>&quot;</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">بما أن عقار إيتوبوسايد &quot;إيبيفيه&quot; يتم إعطاؤه لك من قبل الطبيب أو الممرض(ة)، فمن غير المرجح أن يتم إعطاؤك جرعة زائدة. مع ذلك، إن حدث وتلقيت كمية أكبر مما ينبغي من العقار فسيعالج طبيبك أي أعراض تنجم عن ذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدَّواء، فاستشر طبيبك أو الصيدلي أو الممرض(ة) الخاص(ة) بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواء آثارًا جانبية، على الرَّغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخبر طبيبك أو الممرض</strong><strong>(</strong><strong>ة</strong><strong>) </strong><strong>فورًا إذا أُصبت بأي من الأعراض الآتية</strong><strong>: </strong><strong>تورم اللسان أو الحَلْق، صعوبات بالتنفس، تسارع ضربات القلب، احمرار الجلد أو طفح جلدي</strong><strong>. </strong><strong>قد تكون هذه علامات تنم عن الإصابة بإحدى تفاعلات الحساسية الشديدة</strong><strong>. </strong></p><p dir="RTL">في بعض الأحيان تمت ملاحظة حدوث <strong>تلف</strong> شديد <strong>بالكبد، الكُلى أو القلب</strong> ناجم عن حالة تُدعى متلازمة انحلال الورم نتيجة دخول كميات ضارة من المواد الناتجة عن الخلايا السرطانية إلى مجرى الدَّم عند تلقي عقار إيتوبوسايد &quot;إيبيفيه&quot; بمصاحبة عقاقير أخرى تُستخدم لعلاج السرطان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية المُحتمَلة</strong> التي يتم التعرض لها عند تلقي عقار إيتوبوسايد &quot;إيبيفيه&quot; هي كالآتي:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية شائعة جدًّا</strong> (قد تؤثر على أكثر من شخص واحد من بين كل 10 أشخاص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الدَّم (لذلك ستخضع لاختبارات الدم بين دورات العلاج).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان وقيء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إمساك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر بشكل مؤقت.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلف بالكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة إنزيمات الكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يرقان (زيادة البيليروبين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حدوث تغيرات في لون الجلد (تصبغ الجلد).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالضعف (وهن).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور عام بالإعياء (توعُّك).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالبطن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية شائعة</strong> (قد تؤثر على ما يصل إلى شخص واحد من بين كل 10 أشخاص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الدم الحاد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إِسْهال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات في موضع التسريب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم انتظام ضربات القلب (اضطرابات النظم القلبي) أو نوبة قلبية (احتشاء عضلة القلب).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية شديدة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدَّم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدَّم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقرح الشفتين، قرح بالفم أو الحلق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل جلدية مثل الحكة أو الطفح الجلدي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الوريد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإصابة بالعدوى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية غير شائعة</strong> (قد تؤثر على ما يصل إلى شخص واحد من بين كل 100 شخص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وخز أو تنميل في اليدين والقدمين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية نادرة</strong> (قد تؤثر على ما يصل إلى شخص واحد من بين كل 1000 شخص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتجاع الحمض.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار الجلد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية شديدة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اختلاجات (نوبات تشنجية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمّى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نُعاس أو تعب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان البصر المؤقت.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات خطيرة بالجلد و/أو الأغشية المخاطية التي قد تشمل بثورًا مؤلمة وحُمى، بما في ذلك انفصال الجلد على نِطاقٍ واسِعٍ (متلازمة ستيفنز جونسون وانحلال البشرة النخري التَّسَمُّمِيّ).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي يشبه الحروق الشمسية قد يصيب الجلد الذي تعرَّض سابقًا للعلاج الإشعاعي، ويمكن أن يكون شديدًا (معاودة التهاب الجلد نتيجة التعرض السابق للعلاج الإشعاعي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;صعوبة البلع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حدوث تغير في طريقة تذوُّق الأشياء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل بالتَّنفس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير معروفة </strong>(لا يمكن تقدير معدل التكرار من واقع البيانات المتاحة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة انحلال الورم (مضاعفات ناجمة عن دخول المواد المفرزة من الخلايا السرطانية التي يتم علاجها إلى مجرى الدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه واللسان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العقم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التَّنفس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ هذا الدَّواء بعيدًا عن رؤية ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدَّواء بعد تاريخ انتهاء الصّلاحية المدون على العبوة الكرتونية وعلى الزجاجة بعد كلمة &quot;EXP&quot;. يُشير تاريخ انتهاء الصَّلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">سيتم حفظ عقار إيتوبوسايد &quot;إيبيفيه&quot; في الصيدلية وسيتم إعداده في منطقة خاصة قبل أن يعطيه لك الطبيب أو الممرض(ة).</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُحفَظ في درجة حرارة أقل من 25 درجة مئوية. يُحفَظ داخل العبوة الأصلية.</p><p dir="RTL"><strong><em>عمر التَّخزين الخاص بالمحاليل المُخففة</em></strong><strong><em>: 24 </em></strong><strong><em>ساعة في درجة حرارة تتراوح بين درجتين مئويتين و8 درجات مئوية</em></strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من الأدوية عن طريق إلقائها في مياه الصَّرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه الإجراءات في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي إيتوبوسايد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي: الكحول البنزيلي، إيثانول 96٪، حمض الستريك غير المائي، ماكروجول 300، بوليسوربات 80.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">عقار إيتوبوسايد &quot;إيبيفيه&quot; عبارة عن محلول صافٍ ذي لون أصفر فاتح.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أحجام العبوات:</p><p dir="RTL">عبوة فردية بها زجاجة واحدة تحتوي على 50 مجم/2.5 مللي لتر، 100 مجم/5 مللي لتر، 200 مجم/10 مللي لتر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">عبوات متعددة بها 5 أو 10 زجاجات تحتوي على 50 مجم/2.5 مللي لتر، 100 مجم/5 مللي لتر، 200 مجم/10 مللي لتر.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك حق التسَّویق</strong><br />شركة إيبيفيه فارما المحدودة Nfg.KG</p><p dir="RTL">أ- ٤۸٦٦ أونتراخ، النمسا<br />&nbsp;</p><p dir="RTL"><strong>جھة التصَّنیع</strong><br />شركة فاريفا أونتراخ المحدودة<br />4866 أونتراخ،النمسا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            يوليو 2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Etoposid “Ebewe” 20 mg/ml, concentrate for solution for infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                1 ml of concentrate for solution for infusion contains 20 mg of etoposide.
Each vial of 2.5 ml concentrate for solution for infusion contains 50 mg etoposide.
Each vial of 5 ml concentrate for solution for infusion contains 100 mg etoposide.
Each vial of 10 ml concentrate for solution for infusion contains 200 mg etoposide.

Excipient(s) with known effect
Each 2.5 ml vial contains 50 mg benzyl alcohol and 651.5 mg ethanol.
Each 5 ml vial contains 100 mg benzyl alcohol and 1.303 g ethanol.
Each 10 ml vial contains 200 mg benzyl alcohol and 2.606 g ethanol.

For the full list of excipients see section 6.1

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Concentrate for solution for infusion.

Clear, light yellow solution.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Testicular cancer </strong></p><p>Etoposide is indicated in combination with other approved chemotherapeutic agents for the treatment of first line, recurrent or refractory testicular cancer in adults.</p><p>&nbsp;</p><p><strong>Small cell lung cancer </strong></p><p>Etoposide is indicated in combination with other approved chemotherapeutic agents for the treatment of small-cell lung cancer in adults.</p><p>&nbsp;</p><p><strong>Hodgkin&rsquo;s lymphoma</strong></p><p>Etoposide is indicated in combination with other approved chemotherapeutic agents for the treatment of Hodgkin&rsquo;s lymphoma in adult and paediatric patients.</p><p>&nbsp;</p><p><strong>Non-Hodgkin&rsquo;s lymphoma </strong></p><p>Etoposide is indicated in combination with other approved chemotherapeutic agents for the treatment of non-Hodgkin&rsquo;s lymphoma in adult and paediatric patients.</p><p>&nbsp;</p><p><strong>Acute myeloid leukaemia </strong></p><p>Etoposide is indicated in combination with other approved chemotherapeutic agents for the treatment of acute myeloid leukaemia in adult and paediatric patients.</p><p>&nbsp;</p><p><strong>Gestational trophoblastic neoplasia </strong></p><p>Etoposide is indicated for first line and second line therapy in combination with other approved chemotherapeutic agents for the treatment of high risk gestational trophoblastic neoplasia in adults.</p><p>&nbsp;</p><p><strong>Ovarian cancer </strong></p><p>Etoposide is indicated in combination with other approved chemotherapeutic agents for the treatment of non-epithelial ovarian cancer in adults.</p><p>&nbsp;</p><p>Etoposide is indicated for the treatment of platinum-resistant/refractory epithelial ovarian cancer in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Etoposide should only be administered and monitored under the supervision of a qualified physician experienced in the use of anti-neoplastic medicinal products (see section 4.4).</p><p>&nbsp;</p><p><u>Posology</u></p><p><u>&nbsp;</u></p><p><strong><em>Adult population</em></strong></p><p>The recommended dose of etoposide in adult patients is 50 to 100 mg/m2/day on days 1 to 5 or 100 to 120 mg/m2 on days 1, 3, and 5 every 3 to 4 weeks in combination with other medicinal products indicated in the disease to be treated. Dose should be modified to take into account the myelosuppressive effects of other medicinal products in the combination or the effects of prior radiotherapy or chemotherapy (see section 4.4) which may have compromised bone marrow reserve.</p><p>&nbsp;</p><p>The doses after the initial dose should be adjusted if neutrophil count is below 500 cells/mm<sup>3</sup> for more than 5 days. In addition the dose should be adjusted in case of occurrence of fever, infections, or at a thrombocyte count below 25,000 cells/mm<sup>3</sup>, which is not caused by the disease. Follow up doses should be adjusted in case of occurrence of grade 3 or 4 toxicities or if renal creatinine clearance is below 50 ml/min. At decreased creatinine clearance of 15 to 50 ml/min a dose reduction by 25% is recommended.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><em>Elderly population</em></strong></p><p>No dose adjustment is necessary in elderly patients (age &gt;65 years old), other than based on renal function (see section 5.2).</p><p>&nbsp;</p><p><strong><em>Paediatric population</em></strong><strong><em> </em></strong></p><p><u>Hodgkin&rsquo;s lymphoma; non-Hodgkin&rsquo;s lymphoma; acute myeloid leukaemia </u></p><p><u>&nbsp;</u></p><p>Etoposide in paediatric patients has been used in the range of 75 to 150 mg/m2/day (etoposide equivalent) for 2 to 5 days in combination with other antineoplastic agents. The treatment regimen should be chosen according to the local standard of care.</p><p>&nbsp;</p><p><u>Ovarian cancer; small cell lung cancer; gestational trophoblastic neoplasia; testicular cancer </u></p><p>&nbsp;</p><p>The safety and efficacy of etoposide below 18 years of age have not been established. Currently available data are described in section 5.2 but no recommendation on a posology can be made.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong><em>Renal impairment</em></strong></p><p>In patients with impaired renal function, the following initial dose modification should be considered based on measured creatinine clearance.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:98%"><tbody><tr><td style="vertical-align:top"><p><strong>Measured creatinine clearance</strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Dose of etoposide</strong></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&gt;50 ml/min</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>100% of dose</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>15-50 ml/min</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>75% of dose</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>In patients with creatinine clearance less than 15 ml/min and on dialysis further dose reduction is likely to be required as etoposide clearance is further reduced in these patients (see section 4.4).</p><p>Subsequent dosing in moderate and severe renal impairment should be based on patient tolerance and clinical effect (see section 4.4). Since etoposide and its metabolites are not dialysable, it can be administered pre- and post-haemodialysis (see section 4.9).</p><p><em>&nbsp;</em></p><p><u>Method of administration</u></p><p><u>&nbsp;</u></p><p>Etoposide is administered by slow intravenous infusion (usually over a 30 to 60 minute period) (see section 4.4).</p><p>&nbsp;</p><p>For instructions on reconstitution and dilution of the medicinal product before administration, see section 6.6.</p><p>&nbsp;</p><p><u>Administration Precautions</u></p><p>As with other potentially toxic compounds, caution should be exercised in handling and preparing the solution of etoposide. Skin reactions associated with accidental exposure to etoposide may occur. The use of gloves is recommended. If etoposide solution contacts the skin or mucosa, immediately wash the skin with soap and water and flush the mucosa with water (see section 6.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
•	Lactation (see section 4.6.)
•	Concomitant use of yellow fever vaccine or other live vaccines is contraindicated in immunosuppressed patients (see section 4.5) 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Etoposide should only be administered and monitored under the supervision of a qualified physician experienced in the use of anti-neoplastic medicinal products.</p><p>In all instances where the use of etoposide is considered for chemotherapy, the physician must evaluate the need and usefulness of the medicinal product against the risk of adverse reactions. Most such adverse reactions are reversible if detected early. If severe reactions occur, the medicinal product should be reduced in dose or discontinued and appropriate corrective measures should be taken according to the clinical judgment of the physician. Reinstitution of etoposide therapy should be carried out with caution, and with adequate consideration of the further need for the medicinal product and close attention to possible recurrence of toxicity.</p><p>&nbsp;</p><p><u>Myelosuppression</u></p><p><u>&nbsp;</u></p><p>Dose limiting bone marrow suppression is the most significant toxicity associated with etoposide therapy.</p><p>Fatal myelosuppression has been reported following etoposide administration. Patients being treated with etoposide must be observed for myelosuppression carefully and frequently both during and after therapy. The following haematological parameters should be measured at the start of therapy and prior to each subsequent dose of etoposide: platelet count, haemoglobin, white blood cell count and differential. If radiotherapy or chemotherapy has been given prior to starting etoposide treatment, an adequate interval should be allowed to enable the bone marrow to recover. Etoposide should not be administered to patients with neutrophil counts less than 1,500 cells/mm<sup>3</sup> or platelet counts less than 100,000 cells/mm<sup>3</sup>, unless caused by malignant disease. Doses subsequent to initial dose should be adjusted if neutrophil count less than 500 cells/mm<sup>3</sup> occurs for more than 5 days or is associated with fever or infection, if platelet count less than 25,000 cells/mm<sup>3</sup> occurs, if any grade 3 or 4 toxicity develops or if renal clearance is less than 50 ml/min.</p><p>&nbsp;</p><p>Severe myelosuppression with resulting infection or haemorrhage may occur.</p><p>&nbsp;</p><p>Bacterial infections should be brought under control before treatment with etoposide.</p><p>&nbsp;</p><p><u>Secondary leukaemia</u></p><p>The occurrence of acute leukaemia, which can occur with or without a preleukaemic phase has been described in patients that were treated with etoposide containing chemotherapeutic regimens. Neither the cumulative risk, nor the predisposing factors related to the development of secondary leukaemia are known. The roles of both administration schedules and cumulative doses of etoposide have been suggested, but have not been clearly defined.</p><p>An 11q23 chromosome abnormality has been observed in some cases of secondary leukaemia in patients who have received epipodophyllotoxins. This abnormality has also been seen in patients developing secondary leukaemia after being treated with chemotherapy regimens not containing epipodophyllotoxins and in leukaemia occurring de novo. Another characteristic that has been associated with secondary leukaemia in patients who have received epipodophyllotoxins appears to be a short latency period, with average median time to development of leukaemia being approximately 32 months.</p><p>&nbsp;</p><p><u>Hypersensitivity</u></p><p>Physicians should be aware of the possible occurrence of an anaphylactic reaction with etoposide, manifested by chills, pyrexia, tachycardia, bronchspasm, dyspnea and hypotension, which can be fatal. Treatment is symptomatic, etoposide should be terminated immediately, followed by the administration of pressor agents, corticosteroids, antihistamines, or volume expanders at the discretion of the physician.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Hypotension</u></p><p>Etoposid should be given only by slow intravenous infusion (usually over a 30 to 60&nbsp;minute period). since hypotension has been reported as a possible side effect of rapid intravenous injection.</p><p>&nbsp;</p><p><u>Injection site reaction</u></p><p>Injection site reactions may occur during administration of etoposide. Given the possibility of extravasation, it is recommended to closely monitor the infusion site for possible infiltration during medicinal product administration.</p><p>&nbsp;</p><p><u>Low serum albumin</u></p><p>Low serum albumin is associated with increased exposure to etoposide. Therefore patients with low serum albumin may be at increased risk for etoposide-associated toxicities.</p><p>&nbsp;</p><p><u>Impaired renal function</u></p><p>In patients with moderate (CrCl =15 to 50 ml/min), or severe (CrCl &lt;15ml/min) renal impairment undergoing haemodialysis, etoposide should be administered at a reduced dose (see section 4.2). Haematological parameters should be measured and dose adjustments in subsequent cycles considered based on haematological toxicity and clinical effect in moderate and severe renal impaired patients.</p><p>&nbsp;</p><p><u>Impaired hepatic function</u></p><p>Patients with impaired hepatic function should regularly have their hepatic function monitored due to the risk of accumulation.</p><p>&nbsp;</p><p><u>Tumour lysis syndrome</u></p><p>Tumour lysis syndrome (sometimes fatal) has been reported following the use of etoposide in association with other chemotherapeutic medicinal products. Close monitoring of patients is needed to detect early signs of tumour lysis syndrome, especially in patients with risk factors such as bulky treatment- sensitive tumours, and renal insufficiency. Appropriate preventive measures should also be considered in patients at risk of this complication of therapy.</p><p>&nbsp;</p><p><u>Mutagenic potential</u></p><p>Given the mutagenic potential of etoposide, an effective contraception is required for both male and female patients during treatment and up to 6 months after ending treatment. Genetic consultation is recommended if the patient wishes to have children after ending the treatment. As etoposide may decrease male fertility, preservation of sperm may be considered for the purpose of later fatherhood (see section 4.6).</p><p>&nbsp;</p><p><u>Excipients with known effect</u></p><p>This medicinal product contains 33 vol % &nbsp;ethanol (alcohol), i.e. up to 2345 mg per 180mg (average dose), equivalent to 37ml beer, 15ml wine per average dose.</p><p>&nbsp;</p><p>Harmful for those suffering from alcoholism.</p><p>&nbsp;</p><p>To be taken into account in pregnant or breastfeeding women, children and high risk groups such as patients with liver disease or epilepsy.</p><p>&nbsp;</p><p>The amount of alcohol in this medicinal product may alter the effects of other medicines.</p><p>&nbsp;</p><p>The amount of alcohol in this medicinal product may impair your ability to drive or use machines.</p><p>&nbsp;</p><p>This medicinal product contains 20mg benzyl alcohol in each ml which is equivalent to 180mg per 9ml (average dose). &nbsp;</p><p>&nbsp;</p><p>Benzyl alcohol may cause allergic reactions.</p><p>&nbsp;</p><p>Intravenous administration of benzyl alcohol has been associated with serious adverse events and death in neonates (&ldquo;gasping syndrome&rdquo;). The minimum amount of benzyl alcohol at which toxicity may occur is not known.</p><p>&nbsp;</p><p>Increased risk due to accumulation in young children.</p><p>High volumes should be used with caution and only if necessary, especially in subjects with liver or kidney impairment because of the risk of accumulation and toxicity (metabolic acidosis).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Effects of other medicinal products on the pharmacokinetics of etoposide</u></p><p><u>&nbsp;</u></p><p>High dose ciclosporin, resulting in plasma concentrations above 2000 ng/ml, administered with oral etoposide has led to an 80% increase in etoposide exposure (AUC) with a 38% decrease in total body clearance of etoposide compared to etoposide alone.</p><p>&nbsp;</p><p>Concomitant cisplatin therapy is associated with reduced total body clearance of etoposide.</p><p>&nbsp;</p><p>Concomitant phenytoin therapy is associated with increased etoposide clearance and reduced efficacy, and other enzyme-inducing antiepileptic therapy may be associated with increased etoposide clearance and reduced efficacy.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>In vitro</em> plasma protein binding is 97%. Phenylbutazone, sodium salicylate, and aspirin may displace etoposide from plasma protein binding.</p><p>&nbsp;</p><p><u>Effect of etoposide on the pharmacokinetics of other medicinal products</u></p><p><u>&nbsp;</u></p><p>Co-administration of antiepileptic medicinal products and etoposide can lead to decreased seizure control due to pharmacokinetic interactions between the medicinal products.</p><p>&nbsp;</p><p>Co-administration of warfarin and etoposide may result in elevated international normalized ratio (INR). Close monitoring of INR is recommended.</p><p>&nbsp;</p><p><u>Pharmacodynamic interactions</u></p><p>There is increased risk of fatal systemic vaccinal disease with the use of yellow fever vaccine. Live vaccines are contraindicated in immunosuppressed patients (see section 4.3).</p><p>&nbsp;</p><p>Prior or concurrent use of other medicinal products with similar myelosuppressant action as etoposide may be expected to have additive or synergetic effects (see section 4.4).</p><p>&nbsp;</p><p>Cross resistance between anthracyclines and etoposide has been reported in preclinical experiments.</p><p>&nbsp;</p><p><strong>Paediatric population</strong></p><p>Interaction studies have only been performed in adults.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential/contraception in males and females</u></p><p>Women of childbearing potential should use appropriate contraceptive measures to avoid pregnancy during etoposide therapy.</p><p>&nbsp;</p><p>Etoposide has been shown to be teratogenic in mice and rats (see section 5.3).</p><p>Given the mutagenic potential of etoposide, an effective contraception is required for both male and female patients during treatment and up to 6 months after ending treatment (see section 4.4). Genetic consultation is recommended if the patient wishes to have children after ending the treatment.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>As etoposide may decrease male fertility, preservation of sperm may be considered for the purpose of later fatherhood.</p><p><u>&nbsp;</u></p><p><u>Pregnancy</u></p><p>There are no or limited amount of data from the use of etoposide in pregnant women.</p><p>&nbsp;</p><p>Studies in animals have shown reproductive toxicity (see section 5.3). In general etoposide can cause foetal harm when administered to pregnant women. Etoposide should not be used during pregnancy unless the clinical condition of the woman requires treatment with etoposide.</p><p>Women of child-bearing potential should be advised to avoid becoming pregnant.</p><p>Women of childbearing potential have to use effective contraception during and up to 6 months after treatment.</p><p>&nbsp;</p><p>If this medicinal product is used during pregnancy, or if the patient becomes pregnant while receiving this medicinal product, the patient should be informed of the potential hazard to the foetus.</p><p>&nbsp;</p><p><u>Breastfeeding</u></p><p>Etoposide is excreted in human milk.</p><p>&nbsp;</p><p>There is the potential for serious adverse reactions in nursing infants from etoposide. A decision must be made whether to discontinue breast-feeding or to discontinue etoposide, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman (see section 4.3).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. &nbsp;Etoposide may cause adverse reactions that affect the ability to drive or use machines such as fatigue, somnolence, nausea, vomiting, cortical blindness, hypersensitivity reactions with hypotension.</p><p>Patients who experience such adverse reactions should be advised to avoid driving or using machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p><u>&nbsp;</u></p><p>Dose limiting bone marrow suppression is the most significant toxicity associated with etoposide therapy. In clinical studies in which etoposide was administered as a single agent at a total dose of &ge;450 mg/m<sup>2</sup> the most frequent adverse reactions of any severity were leucopenia (91%), neutropenia (88%), anaemia (72%) thrombocytopenia (23%), asthenia (39%), nausea and/or vomiting (37%), alopecia (33%) and chills and/or fever (24%).</p><p>&nbsp;</p><p><u>Tabulated summary of adverse reactions</u></p><p>The following adverse reactions were reported from etoposide clinical studies and post-marketing experience.</p><p>&nbsp;</p><p>These adverse reactions are presented by system organ class and frequency, which is defined by the following categories: very common (&ge;1/10), common (&ge;1/100, &lt;1/10), uncommon (&ge;1/1,000, &lt;1/100), rare (&ge;1/10,000, &lt;1/1,000), not known (cannot be estimated from the available data).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><thead><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Very common</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td><td style="vertical-align:top"><p><strong>Not known</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Infection</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Neoplasms Benign and Malignant (including cysts and polyps)</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Acute leukemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and the Lymphatic System Disorders*</strong></p></td><td style="vertical-align:top"><p>Myelosuppression*, leucopenia, thrombocytopenia, neutropenia, anemia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune System Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaphylactic reactions**</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Angioedema, bronchospasm</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Tumour lysis syndrome</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous System Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>Peripheral neuropathy</p></td><td style="vertical-align:top"><p>Seizure***, neurotoxicities (e.g., somnolence, fatigue) , cortical blindness transient, optic neuritis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Myocardial infarction, arrythmia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Transient systolic hypotension following rapid intravenous administration, hypertension</p></td><td style="vertical-align:top"><p>Haemorrhage</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, Thoracic and Mediastinal Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Interstitial pneumonitis, pulmonary fibrosis</p></td><td style="vertical-align:top"><p>Bronchospasm</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal Disorders</strong></p></td><td style="vertical-align:top"><p>Abdominal pain, constipation, nausea and vomiting anorexia</p></td><td style="vertical-align:top"><p>Diarrhoeamucositis (including stomatitis and esophagitis)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dysphagia, dysgeusia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary Disorders</strong></p></td><td style="vertical-align:top"><p>Alanine aminotransferase increased, alkaline phosphatase increased, aspartate amino transferase increased, bilirubin increased,Hepatotoxicity</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and Subcutaneous Tissue Disorders </strong></p></td><td style="vertical-align:top"><p>alopecia pigmentation</p></td><td style="vertical-align:top"><p>Pruritus, rash, urticaria</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Stevens-Johnson syndrome, toxic epidermal necrolysis, radiation recall dermatitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Infertility</p></td></tr><tr><td style="vertical-align:top"><p><strong>General Disorders and Administration Site Conditions</strong></p></td><td style="vertical-align:top"><p>Asthenia, malaise,</p></td><td style="vertical-align:top"><p>Extravasation****, phlebitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pyrexia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>* Myelosuppression with fatal outcome has been reported. ** Anaphylactic reactions can be fatal. A higher frequency of anaphylactic reactions in children who received infusions at higher than recommended concentrations, has been reported.</p><p>***Seizure is occasionally associated with allergic reactions.</p><p>**** Postmarketing complications reported for extravasation included local soft tissue toxicity, swelling, pain, celullitis, and necrosis including skin necrosis.</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>In the paragraphs below the incidences of adverse events, given as the mean percent, are derived from studies that utilized single agent etoposide therapy.</p><p>&nbsp;</p><p><em>Hematological Toxicity: </em></p><p>Myelosuppression (see section 4.4) with fatal outcome has been reported following administration of etoposide. Myelosuppression is most often dose-limiting. Bone marrow recovery is usually complete by day 20, and no cumulative toxicity has been reported.</p><p>Granulocyte and platelet nadirs tend to occur about 10-14 days after administration of etoposide or etoposide phosphate depending on the way of administration and treatment scheme. Nadirs tend to occur earlier with intravenous administration compared to oral administration.</p><p>Leukopenia and severe leukopenia (less than 1,000 cells/mm<sup>3</sup>) were observed in 60 - 91% and 7&nbsp;- 17%, respectively, for etoposide/etoposide phosphate. Thrombocytopenia and severe thrombocytopenia (less than 50,000 platelets/mm<sup>3</sup>) were seen in 28 - 41% and 4 - 20%, respectively, for etoposide/etoposide phosphate. Reports of fever and infection were also very common in patients with neutropenia treated with etoposide. Bleeding has been reported.</p><p><strong>&nbsp;</strong></p><p><em>Gastrointestinal Toxicity:&nbsp; </em></p><p>Nausea and vomiting are the major gastrointestinal toxicities of etoposide<strong>. </strong>The nausea and vomiting can usually be controlled by antiemetic therapy.</p><p>&nbsp;</p><p><em>Alopecia:&nbsp; </em></p><p>Reversible alopecia, sometimes progressing to total baldness, has been observed in up to 66% of patients treated with etoposide<strong> </strong>and 44% of patients treated with Etoposide phosphate injection.</p><p>&nbsp;</p><p><em>Hypotension: </em></p><p>Transient hypotension following rapid intravenous administration has been reported in patients treated with etoposide<strong> </strong>and has not been associated with cardiac toxicity or electrocardiographic changes.&nbsp; Hypotension usually responds to cessation of infusion of etoposide and/or other supportive therapy as appropriate.&nbsp; When restarting the infusion, a slower administration rate should be used.</p><p>No delayed hypotension has been noted.</p><p>&nbsp;</p><p><em>Hypertension: </em></p><p>In clinical studies involving etoposide, episodes of hypertension have been reported.&nbsp; If clinically significant hypertension occurs in patients receiving etoposide, appropriate supportive therapy should be initiated.</p><p>&nbsp;</p><p><em>Hypersensitivity</em></p><p>Anaphylactic reactions have been reported to occur during or immediately after intravenous administration of etoposide. The role that concentration or rate of infusion plays in the development of anaphylactic reactions is uncertain.&nbsp; Blood pressure usually normalizes within a few hours after cessation of the infusion. Anaphylactic reactions can occur with the initial dose of etoposide.</p><p>&nbsp;</p><p>Anaphylactic reactions (see section 4.4), manifested by chills, tachycardia, bronchospasm, dyspnoea, diaphoresis, pyrexia, pruritus, hypertension or hypotension, syncope, nausea, and vomiting have been reported to occur in 3% (7 of 245 patients treated with etoposide in 7 clinical studies) of patients treated with etoposide. Facial flushing was reported in 2% of patients and skin rashes in 3%. These reactions have usually responded promptly to the cessation of the infusion and administration of pressor agents, corticosteroids, antihistamines, or volume expanders as appropriate.</p><p>&nbsp;</p><p>Acute fatal reactions associated with bronchospasm have also been reported for etoposide.</p><p>Apnoea with spontaneous resumption of breathing following cessation of infusion have also been reported.</p><p>&nbsp;</p><p><em>Metabolic Complications:</em></p><p>Tumour lysis syndrome (sometimes fatal) has been reported following the use of etoposide<strong> </strong>in association with other chemotherapeutic drugs (see section 4.4).</p><p>&nbsp;</p><p><u>Paediatric population </u></p><p>The safety profile between paediatric patients and adults <u>is expected to be similar.</u></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Total doses of 2.4 g/m<sup>2</sup> to 3.5 g/m<sup>2</sup> administered intraveneously over 3 days have resulted in severe mucositis and myelotoxicity.</p><p>Metabolic acidosis and cases of serious hepatic toxicity have been reported in patients receiving higher doses of etoposide than recommended intravenous doses of etoposide.</p><p>Similar toxicities can be expected with oral formulation.</p><p>A specific antidote is not available. Treatment should therefore be symptomatic and supporting and patients should be closely monitored.</p><p>&nbsp;</p><p>Etoposide and its metabolites are not dialysable.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antineoplastic agents/plant alkaloids and other natural products, podophyllotoxin derivatives, ATC-code: L01CB01.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p><u>&nbsp;</u></p><p>The main effect of etoposide appears to be at the late S and early G2 portion of the cell cycle in mammalian cells. Two dose-dependent responses are seen: At high concentrations (10 &micro;g/ml or more), cells entering mitosis are lysed; at low concentrations (0.3 to 10 &micro;g/ml), cells are inhibited from entering prophase. Microtubule assembly is not affected. The predominant macromolecular effect of etoposide seems to be the rupture of the double strand by an interaction with DNA- topoisomerase II or by the formation of free radicals. Etoposide has been shown to cause metaphase arrest in chick fibroblasts.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>After either intravenous infusion or oral capsule administration, the Cmax and AUC values exhibit marked intra- and inter-subject variability.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>The mean volumes of distribution at steady state range from 18 to 29 liters. Etoposide shows low penetration into the CSF. In vitro, etoposide is highly protein bound (97%) to human plasma proteins.</p><p>&nbsp;</p><p>Etoposide binding ratio correlates directly with serum albumin in cancer patients and normal volunteers (see section 4.4). Unbound fraction of etoposide correlates significantly with bilirubin in cancer patients.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>The hydroxyacid metabolite [4&#39; dimethyl-epipodophyllic acid-9-(4,6 0-ethylidene-&beta;-D-glucopyranoside)], formed by opening of the lactone ring, is found in the urine of adults and children. It is also present in human plasma, presumably as the trans isomer. Glucuronide and/or sulfate conjugates of etoposide are also excreted in human urine. In addition, O-demethylation of the dimethoxyphenol ring occurs through the CYP450 3A4 isoenzyme pathway to produce the corresponding catechol.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>On intravenous administration, the disposition of etoposide is best described as a biphasic process with a distribution half-life of about 1.5 hours and terminal elimination half-life ranging from 4 to 11 hours. Total body clearance values range from 33 to 48 ml/min or 16 to 36 ml/min/m2 and, like the terminal elimination half-life, are independent of dose over a range 100 to 600 mg/m2. After intravenous administration of 14C etoposide (100 to 124 mg/m2), mean recovery of radioactivity in the urine was 56% (45% of the dose was excreted as etoposide) and faecal recovery of radioactivity was 44% of the adminitered dose at 120 hours.</p><p>&nbsp;</p><p><u>Linearity/non-linearity</u></p><p>Total body clearance and the terminal elimination half-life are independent of dose over a range 100 to 600 mg/m2. Over the same dose range, the areas under the plasma concentration vs. time curves (AUC) and the maximum plasma concentration (Cmax) values increase linearly with dose.</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p>Patients with impaired renal function receiving etoposide have exhibited reduced total body clearance, increased AUC and higher steady state volume of distribution (see section 4.2).</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p>In adult cancer patients with liver dysfunction, total body clearance of etoposide is not reduced.</p><p>&nbsp;</p><p><u>Elderly population</u></p><p>Although minor differences in pharmacokinetic parameters between patients &le;65 years and &gt;65 years of age have been observed, these are not considered clinically significant.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>In children, approximately 55% of the dose is excreted in the urine as etoposide in 24 hours. The mean renal clearance of etoposide is 7 to 10 ml/min/m2 or about 35% of the total body clearance over a dose range of 80 to 600 mg/m2. Etoposide, therefore, is cleared by both renal and nonrenal processes, ie, metabolism and biliary excretion. The effect of renal disease on plasma etoposide clearance is not known in children. In children, elevated SGPT levels are associated with reduced active substance total body clearance. Prior use of cisplatin may also result in a decrease of etoposide total body clearance in children.</p><p>&nbsp;</p><p>An inverse relationship between plasma albumin levels and etoposide renal clearance is found in children.</p><p>&nbsp;</p><p><u>Gender</u></p><p>Although minor differences in pharmacokinetic parameters between genders have been observed, these are not considered clinically significant.</p><p>&nbsp;</p><p><u>Drug interactions</u></p><p>In a study of the effects of other therapeutic agents on in vitro binding of 14C etoposide to human serum proteins, only phenylbutazone, sodium salicylate, and aspirin displaced protein-bound etoposide at concentrations generally achieved in vivo (see section 4.5).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Chronic toxicity</u></p><p>Anaemia, leucopenia, and thrombocytopenia were observed in rats and mice, while dogs had mild reversible deterioration of liver and kidney functions. The dose multiple (based on mg/m2 doses) for these findings at the no-observed adverse-effect-level in the preclinical studies were &ge; approximately 0.05 times compared to the highest clinical dose. Historically, preclinical species have been more sensitive compared to humans towards cytotoxic agents. Testicular atrophy, spermatogenesis arrest, and growth retardation were reported in rats and mice.</p><p>&nbsp;</p><p><u>Mutagenicity</u></p><p>Etoposide is mutagenic in mammalian cells.</p><p>&nbsp;</p><p><u>Reproductive toxicity</u></p><p>In animal studies etoposide was associated with dose-related embryotoxicity and teratogenicity.</p><p>&nbsp;</p><p><u>Carcinogenic potential</u></p><p>Given its mechanism of action, etoposide should be considered a possible carcinogen in humans.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Benzyl alcohol</p><p>Ethanol 96%</p><p>Anhydrous citric acid</p><p>Macrogol 300</p><p>Polysorbate 80</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Etoposid &ldquo;Ebewe&rdquo; should not be physically mixed with any other drug except for the medicinal products declared in section 6.6.</p><p>&nbsp;</p><p>Plastic devices made of acrylic or ABS polymers have been reported to crack when used with undiluted Etoposid &ldquo;Ebewe&rdquo; concentrate for solution for infusion 20mg/ml. This effect has not been reported with Etoposid &ldquo;Ebewe&rdquo; after dilution of the concentrate for solution for infusion according to instructions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 2 years (before reconstitution).

Diluted solutions: 24 hours
Chemical and physical in-use stability has been demonstrated for 24 hours at room temperature. From a microbiological point of view, the diluted medicinal product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8oC, unless dilution has taken place in controlled and validated aseptic conditions. See section 6.6.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 25&deg;C. Store in the original package.</p><p>&nbsp;</p><p>For storage conditions after reconstitution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Amber vials of Type I glass according to Ph.Eur.</p><p>&nbsp;</p><p>Etoposid &ldquo;Ebewe&rdquo; is available in individual pack containing 1 vial with 50 mg/2.5 ml, 100 mg/5ml, 200 mg/10 ml.</p><p>&nbsp;</p><p>Etoposid &ldquo;Ebewe&rdquo; is available in multi packs containing 5 or 10 vials with 50 mg/2.5 ml, 100 mg/5ml, 200 mg/10 ml.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;The vials are closed with fluoropolymer-coated chlorobutyl rubber stoppers according to Ph.Eur.&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Handle according to guidelines for cytotoxics.</p><p>Concentrate for solution for infusion must not be used undiluted.</p><p>&nbsp;</p><p>Immediately before administration, the required dose of Etoposid &ldquo;Ebewe&rdquo; must be diluted in glucose 5% or 0.9% saline solution for injection to give a concentration range from 0.2 to 0.4mg/ml, usually not more than 0.25mg/ml for the final concentration. It should then be given by intravenous infusion over a period of not less than 30 minutes.</p><p>&nbsp;</p><p>The concentration of etoposide in the reconstituted solution for infusion should not exceed 0.4 mg/ml due to the risk of precipitation.</p><p>&nbsp;</p><p>As with other potentially cytotoxic compounds caution should be exercised when handling etoposide (gloves, mask, overall). Contact with skin and mucous membranes should be avoided.</p><p>&nbsp;</p><p>If etoposide comes into contact with skin wash with water.</p><p>&nbsp;</p><p>Only for intravenous use.</p><p>Single use only.</p><p>Unused solution should be discarded.</p><p>Syringes, containers, absorbent materials, solution and any other contaminated material should be placed in a designated impervious container and incinerated, in accordance with local procedures.</p><p>Any unused product or waste material should be disposed of in accordance with local requirements.</p><p>Only clear solutions practically free from particles should be used.</p><p>&nbsp;</p><p>Cytotoxics should not be handled by pregnant personnel.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                EBEWE Pharma Ges.m.b.H. Nfg.KG, Unterach, AUSTRIA


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                07/2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>